MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Humanigen ROE Ratio 2011-2026 | HGEN
Annual ROE Ratio Humanigen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 151.25 | 999.02 | -196.59 | 71.9 | 148.01 | 90.35 | 617.01 | -617.2 | -154.38 | -69.3 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 999.02 | -617.2 | 104.01 |
Quarterly ROE Ratio Humanigen
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 159.02 | 190.35 | 568.6 | 901.64 | 679.41 | -168.95 | -236.47 | -682.24 | -572.95 | -125.68 | -108.99 | -24.79 | 51.27 | 57.75 | 84.58 | 94.72 | 104.31 | 122.45 | 151.98 | 154.67 | 147.06 | 77.61 | 180.9 | 254.66 | 503.68 | 501.51 | 386.36 | 167.93 | -211.75 | -388.38 | -427.84 | -345.46 | -279.96 | -154.38 | -131.83 | -117.78 | -97.42 | -69.29 | -40.07 | -12.29 | 9.41 | 24.76 | 13.79 | 6.08 | 5.52 | - | 1.35 | 1.63 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 901.64 | -682.24 | 29.93 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.54 | -0.56 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-28.74 | $ 3.2 | 2.24 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-138.5 | $ 4.17 | -1.18 % | $ 105 M | Schweiz |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.8 | 1.81 % | $ 4.36 M | China |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 6.55 | -1.21 % | $ 179 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.41 | -5.54 % | $ 8.2 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 229.89 | -0.49 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
BioCardia
BCDA
|
721.83 | $ 1.28 | 0.55 % | $ 27.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-57.49 | $ 6.12 | 1.16 % | $ 499 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 3.51 | -2.23 % | $ 7.64 B | Israel |
 |
Catalyst Biosciences
CBIO
|
9.32 | $ 11.32 | -2.25 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.64 | 1.92 % | $ 215 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
CNS Pharmaceuticals
CNSP
|
-240.55 | $ 2.28 | -6.94 % | $ 872 K | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.64 | - | $ 16.6 M | USA |
 |
Curis
CRIS
|
723.39 | $ 0.88 | 2.58 % | $ 5.55 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.51 | - | $ 385 M | Britain |
 |
BioNTech SE
BNTX
|
1.11 | $ 92.24 | 1.88 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-216.19 | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |